Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Cash from Financing Activities (2016 - 2023)

Historic Cash from Financing Activities for Alaunos Therapeutics (TCRT) over the last 12 years, with Q2 2023 value amounting to -$12.0 million.

  • Alaunos Therapeutics' Cash from Financing Activities changed N/A to -$12.0 million in Q2 2023 from the same period last year, while for Mar 2024 it was -$12.0 million, marking a year-over-year decrease of 583205.74%. This contributed to the annual value of -$18.1 million for FY2023, which is 38487.51% down from last year.
  • According to the latest figures from Q2 2023, Alaunos Therapeutics' Cash from Financing Activities is -$12.0 million.
  • Alaunos Therapeutics' Cash from Financing Activities' 5-year high stood at $101.7 million during Q1 2020, with a 5-year trough of -$12.0 million in Q2 2023.
  • For the 4-year period, Alaunos Therapeutics' Cash from Financing Activities averaged around $9.7 million, with its median value being $23000.0 (2020).
  • Examining YoY changes over the last 5 years, Alaunos Therapeutics' Cash from Financing Activities showed a top increase of 9221851.85% in 2021 and a maximum decrease of 14650.0% in 2021.
  • Quarter analysis of 4 years shows Alaunos Therapeutics' Cash from Financing Activities stood at $400000.0 in 2020, then plummeted by 146.5% to -$186000.0 in 2021, then skyrocketed by 4655.91% to $8.5 million in 2022, then crashed by 241.37% to -$12.0 million in 2023.
  • Its last three reported values are -$12.0 million in Q2 2023, -$6.2 million for Q1 2023, and $8.5 million during Q4 2022.